Literature DB >> 7320182

Reversed-phase high-performance liquid chromatographic assay for the antineoplastic agent 9,10-anthracenedicarboxaldehyde bis(4,5-dihydro-1H-imidazol-2-yl hydrazone) dihydrochloride.

G Powis.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 7320182     DOI： 10.1016/s0378-4347(00)86091-0

Source DB:  PubMed          Journal:  J Chromatogr


× No keyword cloud information.
  4 in total

1.  Blood and tissue concentrations of Bisantrene measured by a simple fluorometric assay.

Authors:  M Buck; J S Kovach
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

2.  Regional targeting of bisantrene by directed intravascular precipitation.

Authors:  J S Kovach; M Buck; T Tsukamoto; A Odegaard; M M Lieber
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

3.  A phase I and pharmacokinetic comparison of hepatic arterial and peripheral vein infusions of bisantrene for liver cancer.

Authors:  G R Weiss; M Hersh; J G Kuhn; T M Ludden; D D von Hoff; D L Kisner; T E Pirtle
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

4.  Characterization of the pharmacokinetics of bisantrene (NSC-337766).

Authors:  J G Kuhn; T M Ludden; J W Myers; D D Von Hoff
Journal:  Invest New Drugs       Date:  1983       Impact factor: 3.850
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.